Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]

9183 reported adverse events

Drugs of this class: BENRALIZUMAB

These side effects are most commonly reported by patients taking drugs of the Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] class:

# Side effect Count
0 ASTHMA 1671
1 DYSPNOEA 1033
2 DRUG INEFFECTIVE 767
3 DEATH 653
4 HEADACHE 608
5 COUGH 540
6 WHEEZING 481
7 PYREXIA 379
8 RASH 360
9 MALAISE 341
See all common reactions for Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]

Drugs of the Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EOSINOPHILIC OTITIS MEDIA 6 0.3750
1 CHRONIC EOSINOPHILIC RHINOSINUSITIS 4 0.2222
2 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS 70 0.0649
3 FRACTIONAL EXHALED NITRIC OXIDE INCREASED 6 0.0632
4 EOSINOPHIL COUNT ABNORMAL 35 0.0619
5 CHRONIC RHINOSINUSITIS WITH NASAL POLYPS 2 0.0606
6 EOSINOPENIA 5 0.0556
7 FORCED EXPIRATORY VOLUME ABNORMAL 5 0.0427
8 BACTERIAL DISEASE CARRIER 22 0.0386
9 BRONCHIAL WALL THICKENING 20 0.0341
See all enriched reactions for Interleukin-5 Receptor alpha-directed Cytolytic Antibody [EPC]